CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...
Add Yahoo as a preferred source to see more of our stories on Google. A nurse draws up doses of the Moderna COVID-19 for a vaccination clinic in St. Helena in 2021. Moderna is offering a new, low-dose ...
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License ...
Moderna, Inc. MRNA shares are trading higher Tuesday after the company announced European Commission marketing authorization ...
NEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe ...
Moderna’s COVID-19 vaccines have been generally well-tolerated. The most common solicited local adverse event for Moderna’s COVID-19 vaccines is injection site pain. The most common solicited systemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results